Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Efficacy and Safety of Rezvilutamide Combined With Docetaxel in the Treatment of Abiraterone-resistant Prostate Cancer.

NCT07112209 is registered in ClinicalTrials.gov with Zhujiang Hospital as lead sponsor.

NCT NCT07112209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07112209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Efficacy and Safety of Rezvilutamide Combined With Docetaxel in the Treatment of Abiraterone-resistant Prostate Cancer.
Lead sponsor
Zhujiang Hospital
Phase
Not applicable
Overall status
Enrolling by invitation
Start date
November 6, 2023
Completion date
November 6, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pathological and imaging examinations confirmed metastatic prostate cancer